InsidersTradesSigma
Track the Kiora Pharmaceuticals INC share price and the full insider trade history of the company, a publicly traded company based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Kiora Pharmaceuticals INC has logged 39 reports. The latest transaction was filed on 2 April 2026 (Retenue fiscale). Among the most active insiders: Daniels Eric Joseph. Every trade is accessible without an account.
39
Insider Decl.
n/a
Thresholds
€87,424
9 ops.
Buy Volume
n/a
n/a
Sell Volume
51Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 2 April 2026
Declarations39 total
929 shares@ US$1.9518.1% of flowCommon StockSEC:0001372514-26-000032:0
1,906 shares@ US$1.954.4% of flowCommon StockSEC:0001372514-26-000030:0
929 shares@ US$1.9519.8% of flowCommon StockSEC:0001372514-26-000034:0
6,533 shares0Common StockSEC:0001372514-26-000014:0
16,733 shares0Common StockSEC:0001372514-26-000013:0
6,533 shares0Common StockSEC:0001372514-26-000012:0
238 shares@ US$2.024.6% of flowCommon StockSEC:0001372514-26-000007:0
238 shares@ US$2.020.6% of flowCommon StockSEC:0001372514-26-000006:0
7,772 shares0Common StockSEC:0001372514-25-000036:0
15,941 shares0Common StockSEC:0001372514-25-000034:0
7,772 shares0Common StockSEC:0001372514-25-000035:0
1,250 shares@ US$3.68100.0% of flowCommon StockSEC:0001372514-24-000115:0
Canonical exit: 10 Dec 2024 (T+90)
3,000 shares@ US$3.60100.0% of flowCommon StockSEC:0001372514-24-000113:0
Canonical exit: 9 Dec 2024 (T+90)
1,250 shares@ US$3.86100.0% of flowCommon StockSEC:0001372514-24-000111:0
Canonical exit: 17 Nov 2024 (T+90)
5,000 shares@ US$3.96100.0% of flowCommon StockSEC:0001372514-24-000109:0
Canonical exit: 17 Nov 2024 (T+90)
2,000 shares@ US$3.2192.3% of flowCommon StockSEC:0001372514-24-000107:0
Canonical exit: 12 Nov 2024 (T+90)
7,355 shares0Common StockSEC:0001372514-24-000094:0
15,629 shares0Common StockSEC:0001372514-24-000097:0
7,620 shares0Common StockSEC:0001372514-24-000096:0
100 shares@ US$5.257.7% of flowCommon StockSEC:0001372514-24-000065:0
Canonical exit: 12 Sept 2024 (T+90)
1,431 shares@ US$5.29100.0% of flowCommon StockSEC:0001372514-24-000063:0
Canonical exit: 12 Sept 2024 (T+90)
5,260 shares@ US$4.88100.0% of flowCommon StockSEC:0001372514-24-000061:0
Canonical exit: 11 Sept 2024 (T+90)
3,000 shares@ US$4.99919.9% of flowCommon StockSEC:0001372514-24-000060:0
Canonical exit: 11 Sept 2024 (T+90)
30,000 shares0Common StockSEC:0001372514-23-000150:0
62,500 shares0Common StockSEC:0001372514-23-000149:0
25 of 39 declarations
关于 Kiora Pharmaceuticals INC
Kiora Pharmaceuticals Inc. 是一家在美国纳斯达克上市的生物制药公司，股票代码为KPRX，也是SEC Form 4内部交易申报中提及的发行人。Kiora总部位于美国加利福尼亚州恩西尼塔斯，专注于眼科领域，其开发策略以针对严重视网膜疾病的创新疗法为中心。该公司于2004年12月28日在特拉华州注册成立，这使其在生物技术领域拥有悠久的运营历史，尽管它仍是一家临床阶段公司，而非商业阶段的制药平台。([sec.gov](https://www.sec.gov/Archives/edgar/data/1372514/000137251426000047/kprx-20260331.htm?utm_source=openai)) Kiora作为一家专注于眼科产品的单一业务专业制药公司运营。其管线目前以两个主要项目为核心。KIO-301正在开发用于遗传性视网膜疾病，特别是视网膜色素变性，旨在靶向存活的视网膜神经节细胞。KIO-104是一种抗炎候选药物，旨在治疗视网膜炎症，包括视网膜黄斑水肿。这些项目构成了公司投资案例的核心。目前，Kiora不具备大型制药公司多元化的商业组合或收入基础；相反，它主要依赖于临床执行、监管进展和资本获取。([kiorapharma.com](https://kiorapharma.com/technology/kio-301/?utm_source=openai)) 从竞争角度来看，Kiora在竞争激烈的眼科市场中是一个利基参与者，该市场由拥有更多临床、监管和商业资源的大公司主导。其差异化在于专注于罕见视网膜疾病，这些疾病的医疗需求仍未得到满足，并且成功的概念验证数据可能创造合作或许可机会。然而，这种专注也集中了风险：公司的估值对试验结果、监管里程碑和融资条件高度敏感。([ir.kiorapharma.com](https://ir.kiorapharma.com/news-events/news-releases/detail/152/kiora-pharmaceuticals-receives-clinical-trial-approval-for-first-in-human-evaluation-of-kio-301-to-restore-vision-in-patients-with-retinitis-pigmentosa?utm_source=openai)) 最近的公司发展非常重要。2026年3月，Kiora报告了两个活跃的2期研究的进展，包括KIO-301的ABACUS-2和KIO-104的KLARITY。2026年4月，公司宣布了一项涉及普通股和认股权证的股权融资，强调了在开发阶段模式下持续的资本管理。其2026年3月31日的季度文件指出，根据现金和短期投资以及2026年4月的融资收益，Kiora预计将为计划运营提供资金至2028年末。对于投资者而言，这使得Kiora成为美国纳斯达克市场上一家高风险、高回报的眼科生物技术公司，其价值创造主要与临床和监管成功相关。([ir.kiorapharma.com](https://ir.kiorapharma.com/sec-filings/all-sec-filings/content/0001372514-26-000025/ex991-pressreleasedecember.htm?utm_source=openai))
